Compare Stocks → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:ANVSNASDAQ:ENLVNASDAQ:ONCYNASDAQ:PHASOTCMKTS:XYNO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANVSAnnovis Bio$11.91+3.6%$10.39$5.42▼$22.49$126.52M1.59183,489 shs226,539 shsENLVEnlivex Therapeutics$1.32+3.9%$3.26$1.15▼$4.59$23.58M1.02362,024 shs48,007 shsONCYOncolytics Biotech$1.06+1.9%$1.07$0.88▼$3.39$78.44M1.93259,005 shs55,895 shsPHASPhaseBio Pharmaceuticals$0.00$0.07▼$4.08$3.50M2.57848,888 shsN/AXYNOXynomic Pharmaceuticals$2.22$2.22$0.20▼$3.84N/AN/AN/AN/AInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANVSAnnovis Bio+3.61%+18.93%+5.26%+30.97%-19.62%ENLVEnlivex Therapeutics+3.94%-8.97%-64.13%-56.00%-53.52%ONCYOncolytics Biotech+1.92%-1.85%+6.00%-11.67%-6.19%PHASPhaseBio Pharmaceuticals0.00%0.00%0.00%0.00%-76.19%XYNOXynomic Pharmaceuticals0.00%0.00%0.00%0.00%0.00%A new way to collect income from stocks (Ad)Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANVSAnnovis Bio1.1284 of 5 stars3.41.00.00.01.21.70.6ENLVEnlivex Therapeutics2.9746 of 5 stars3.55.00.00.01.90.81.3ONCYOncolytics Biotech0.826 of 5 stars3.53.00.00.00.60.00.0PHASPhaseBio PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AXYNOXynomic PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANVSAnnovis Bio2.75Moderate Buy$27.75133.10% UpsideENLVEnlivex Therapeutics3.00Buy$7.00430.30% UpsideONCYOncolytics Biotech3.00Buy$4.00277.36% UpsidePHASPhaseBio PharmaceuticalsN/AN/AN/AN/AXYNOXynomic PharmaceuticalsN/AN/AN/AN/ACurrent Analyst RatingsLatest PHAS, XYNO, ENLV, ONCY, and ANVS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/23/2024ENLVEnlivex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.004/12/2024ENLVEnlivex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $7.004/4/2024ONCYOncolytics BiotechRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$3.004/2/2024ANVSAnnovis BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.003/21/2024ANVSAnnovis BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.002/28/2024ANVSAnnovis BioBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$9.002/14/2024ONCYOncolytics BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANVSAnnovis BioN/AN/AN/AN/A($0.73) per shareN/AENLVEnlivex TherapeuticsN/AN/AN/AN/A$1.62 per shareN/AONCYOncolytics BiotechN/AN/AN/AN/A$0.27 per shareN/APHASPhaseBio Pharmaceuticals$818K0.00N/AN/A($1.93) per share0.00XYNOXynomic PharmaceuticalsN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANVSAnnovis Bio-$56.20M-$6.22N/AN/AN/AN/A-446.06%-257.97%5/9/2024 (Estimated)ENLVEnlivex Therapeutics-$29.07M-$1.56N/AN/AN/AN/A-71.00%-59.08%6/21/2024 (Estimated)ONCYOncolytics Biotech-$20.56M-$0.30N/AN/AN/AN/A-105.97%-72.80%5/3/2024 (Estimated)PHASPhaseBio Pharmaceuticals-$131.07M-$2.13N/AN/AN/A-12,572.13%N/A-174.38%N/AXYNOXynomic PharmaceuticalsN/AN/A0.00∞N/AN/AN/AN/AN/ALatest PHAS, XYNO, ENLV, ONCY, and ANVS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/7/2024Q4 2023ONCYOncolytics Biotech-$0.11-$0.04+$0.07-$0.04N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANVSAnnovis BioN/AN/AN/AN/AN/AENLVEnlivex TherapeuticsN/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/AN/APHASPhaseBio PharmaceuticalsN/AN/AN/AN/AN/AXYNOXynomic PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANVSAnnovis BioN/A2.392.39ENLVEnlivex TherapeuticsN/A5.577.34ONCYOncolytics BiotechN/A9.019.01PHASPhaseBio PharmaceuticalsN/A0.470.47XYNOXynomic PharmaceuticalsN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipANVSAnnovis Bio15.83%ENLVEnlivex Therapeutics1.02%ONCYOncolytics Biotech6.82%PHASPhaseBio Pharmaceuticals49.02%XYNOXynomic PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipANVSAnnovis Bio38.30%ENLVEnlivex Therapeutics12.28%ONCYOncolytics Biotech0.10%PHASPhaseBio Pharmaceuticals9.90%XYNOXynomic Pharmaceuticals86.29%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableANVSAnnovis Bio611.01 million6.79 millionOptionableENLVEnlivex Therapeutics5018.57 million16.29 millionOptionableONCYOncolytics Biotech2975.42 million75.35 millionNot OptionablePHASPhaseBio Pharmaceuticals6049.86 million44.92 millionNot OptionableXYNOXynomic Pharmaceuticals27N/AN/ANot OptionablePHAS, XYNO, ENLV, ONCY, and ANVS HeadlinesSourceHeadlineWatson Pharmaceuticalsforbes.com - February 21 at 10:13 PMElite Pharmaceuticals Inc.wsj.com - February 14 at 12:30 PMHDAC Inhibitor Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightfinance.yahoo.com - January 8 at 3:26 PMFennec Pharmaceuticals Inc FENCmorningstar.com - November 1 at 1:58 AMStarfield:Pharmaceuticalsvideogamer.com - September 26 at 5:59 PMDelveInsight Highlights Major Advances, Transformative Therapies, and 195+ Leading Players Wheeling the Glioblastoma Clinical Trial Pipeline Landscapebenzinga.com - September 1 at 8:35 PMGlaxosmithkline Pharmaceuticalslivemint.com - July 8 at 4:16 PMCompany History - Paam Pharmaceuticalsmoneycontrol.com - May 30 at 7:13 AMGlenmark Pharmaceuticals Get USFDA Nod For Human Trial Of Advanced Cancer-Treating Drugoutlookindia.com - March 18 at 3:41 PMDelveInsight Evaluates a Robust High-grade Glioma Pipeline as 120+ Influential Pharma Players to Set Foot in the Domainfinance.yahoo.com - March 13 at 6:05 PMPharmaceutical Secondary Packaging Equipment Market 2022 Key Product Segments, Application Analysis, and Industry Growth Forecast by 2028marketwatch.com - October 7 at 12:35 AMP53 Antagonist Shows Early Activity in Advanced Liposarcomamedpagetoday.com - June 8 at 9:53 PMSelinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trialascopubs.org - April 10 at 9:25 AMFollicular Lymphoma Market to Witness Expansion at a 6.85% CAGR during the Study Period [2018-2030], States DelveInsightfinance.yahoo.com - February 9 at 12:55 PMXynomic Pharmaceuticals Holdings Inc (XYNO)investing.com - January 5 at 10:07 PMFollicular Lymphoma Market Size 2021: CAGR Value, Top Manufacturers, Industry Share, Growth, Supply Demand and Forecast till 2026wboc.com - November 10 at 7:29 PMFollicular Lymphoma Drug Landscape Report 2021 - ResearchAndMarkets.comnz.finance.yahoo.com - August 7 at 7:01 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to ComeCan Altimmune get its GLP-1 Drug to Market Before Cash Rush Out? April 9, 2024 6:07 AMView Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out? Penny Stock Quantum-Si Incorporated Readies For Lift-OffApril 9, 2024 7:14 AMView Penny Stock Quantum-Si Incorporated Readies For Lift-OffAll Headlines Company DescriptionsAnnovis BioNYSE:ANVSAnnovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.Enlivex TherapeuticsNASDAQ:ENLVEnlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.Oncolytics BiotechNASDAQ:ONCYOncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.PhaseBio PharmaceuticalsNASDAQ:PHASPhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.Xynomic PharmaceuticalsOTCMKTS:XYNOXynomic Pharmaceuticals Holdings, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule drug candidates for the treatment of cancer in the People's Republic of China and the United states. Its lead drug candidate is Abexinostat, an orally dosed hydroxamic acid-based small molecule histone deacetylase inhibitor. The company develops pazopanib a molecular therapy for treating renal cell carcinoma; XYN-603 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory (R/R) mantle cell lymphoma or R/R diffuse large b-cell lymphoma (DLBCL); and XYN-604, which is in phase 1b trial for treatment of multiple solid tumors. It also develops single agent monotherapy products that is in phase II clinical trial, including XYN-601 for treatment of R/R follicular lymphoma (FL); XYN-606 to treat R/R DLBCL; and XYN-605 for treatment of R/R FL. In addition, the company develops drug candidate XP-105, a mTORC1/2 inhibitor, which has completed Phase I clinical trial for treatment of breast cancer. Further, its pre-clinical oncology drug candidate include XP-102 (BI 882370), a pan-RAF inhibitor. The company was founded in 2016 and is headquartered in Shanghai, China. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.